2. Search Result
Search Result
Results for "

pS6

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161235
    BTX-7312

    		SOS1 Molecular Glues Ras Cancer
    BTX-7312 is a cereblon-based SOS1 bifunctional degrader and a molecular glue. BTX-7312 reduces downstream signaling markers pERK and pS6 and shows antiproliferative activity in various KRAS-mutated cells .
    BTX-7312
  • HY-14463
    Onalespib
    Maximum Cited Publications
    11 Publications Verification

    AT13387

    		 HSP Cancer
    Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) .
    Onalespib
  • HY-154957
    mTOR inhibitor-11

    		mTOR Neurological Disease
    mTOR inhibitor-11 (Compound 9) is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6). mTOR inhibitor-11 also inhibits pCHK1 and PDE4D with IC50s of 17.2 and 17.0 μM. mTOR inhibitor-11 can be used for research of CNS disease .
    mTOR inhibitor-11
  • HY-142656
    PIM-IN-1

    		Pim Cancer
    PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC50 = 61 nM; pS6, EC50 = 71 nM).
    PIM-IN-1
  • HY-170670
    DQ661

    		Autophagy mTOR Cancer
    DQ661 is a potent PPT1 inhibitor. DQ661 is a dimeric quinacrine autophagy inhibitor. DQ661 inhibits mTORC1 activity. DQ661 decreases the protein expression of pS6K T389, pS6 S240-244. DQ661 shows anticancer activity .
    DQ661
  • HY-161236
    KRAS ligand 4

    		Molecular Glues SOS1 Ras Cancer
    KRAS ligand 4 (compound 2) is a bifunctional molecular glue degrader based on SOS1. KRAS ligand 4 reduces downstream signaling markers pERK and pS6 and displays anti-additional activity in cells with multiple KRAS mutations .
    KRAS ligand 4
  • HY-161233
    BTX-6654

    		SOS1 PROTACs ERK Cancer
    BTX-6654 is a target-dependent and -specific cereblon-based bifunctional SOS1 PROTAC degrader. BTX-6654 reduces downstream signaling markers pERK and pS6, and displays antiproliferative activity in cells harboring various KRAS mutations .
    BTX-6654
  • HY-111370
    mTOR inhibitor-2

    		mTOR Cancer
    mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates .
    mTOR inhibitor-2
  • HY-168884
    AV457

    		mTOR Metabolic Disease
    AV457 is a potent and selective mTOR inhibitor with an IC50 value of 0.54 µM. AV457 inhibits cyst growth in polycystic kidney disease (PKD) organoids. AV457 decreases the protein expression of P-s6, P-p70s6 and don’t decreases the protein expression of P-AKT .
    AV457
  • HY-113916
    Onalespib lactate

    AT13387 lactate

    		 HSP Cancer
    Onalespib lactate is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor with an Kd value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC) .
    Onalespib lactate
  • HY-146223
    AZD4625

    		Ras p38 MAPK PI3K Apoptosis Cancer
    AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
    AZD4625
  • HY-145931
    CC214-2

    		mTOR Autophagy Cancer
    CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .
    CC214-2
  • HY-124348
    DM-PIT-1

    3,5-Dimethyl PIT-1

    		 PI3K Cancer
    DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer .
    DM-PIT-1
  • HY-148273
    Setidegrasib

    ASP-3082; KRAS G12D inhibitor 17

    		 PROTACs Ras ERK Akt Cancer
    Setidegrasib (KRAS G12D inhibitor 17, ASP3082) is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib suppresses p-ERK, p-AKT, p-S6 levels in AsPC-1 cells. Setidegrasib exhibits anti-tumor activity in various cancer xenograft models in mice. Setidegrasib can be used for the study of KRAS(G12D)-mutated solid tumors. (Blue: VHL ligase ligand (HY-168699); Black: linker (HY-168698); Pink: G12D ligand (HY-168700)) .
    Setidegrasib
  • HY-146223A
    (3R,10R,14aS)-AZD4625

    		Ras PI3K p38 MAPK Apoptosis Cancer
    (3R,10R,14aS)-AZD4625 is the isomer of AZD4625 (HY-146223), and can be used as an experimental control. AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
    (3R,10R,14aS)-AZD4625
  • HY-132168
    RMC-5552
    3 Publications Verification

    		 mTOR Cancer
    RMC-5552 is a potent and selective mTORC1 inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC50 of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity .
    RMC-5552
  • HY-134656
    BC1618
    1 Publications Verification

    		 AMPK Mitophagy E1/E2/E3 Enzyme Metabolic Disease Inflammation/Immunology
    BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity .
    BC1618
  • HY-100501
    M2698
    1 Publications Verification

    MSC2363318A

    		 Ribosomal S6 Kinase (RSK) Akt Cancer
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .
    M2698
  • HY-124798
    Rheb inhibitor NR1
    3 Publications Verification

    		 mTOR Neurological Disease Inflammation/Immunology Cancer
    Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity .
    (Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
    Rheb inhibitor NR1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: